203 related articles for article (PubMed ID: 19294626)
41. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma.
Yu X; Zhao H; Liu L; Cao S; Ren B; Zhang N; An X; Yu J; Li H; Ren X
J Clin Immunol; 2014 Feb; 34(2):194-203. PubMed ID: 24337625
[TBL] [Abstract][Full Text] [Related]
42. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
Sievers E; Albers P; Schmidt-Wolf IG; Märten A
J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
[TBL] [Abstract][Full Text] [Related]
44. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
45. [Clinical experiment of cytokines induced killer cells for treatment of benzene poisoning].
Liu WW; Chen JY; Yu W; Yang ZQ; Wu LB; Zhang C; Yang DM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Sep; 25(9):546-9. PubMed ID: 17997890
[TBL] [Abstract][Full Text] [Related]
46. [Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy].
Takeda T; Watanabe M; Umeshita K; Goto M; Monden M
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1646-8. PubMed ID: 15553671
[TBL] [Abstract][Full Text] [Related]
47. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection.
Shi M; Fu J; Shi F; Zhang B; Tang Z; Jin L; Fan Z; Zhang Z; Chen L; Wang H; Lau GK; Wang FS
Clin Immunol; 2009 Jul; 132(1):43-54. PubMed ID: 19328038
[TBL] [Abstract][Full Text] [Related]
48. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
49. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
50. Restoration of CD3
Dai H; Zhou Y; Tong C; Guo Y; Shi F; Wang Y; Shen P
Cytotherapy; 2018 Sep; 20(9):1155-1163. PubMed ID: 30100374
[TBL] [Abstract][Full Text] [Related]
51. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
52. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
53. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
54. [Evaluation of in vivo labeled cytotoxic T lymphocytes and cytokine-induced killer cells migration and distribution of subcutaneous gastric tumor model in nude mice].
Wu ZY; DU XH; Xu YX; Li L; Liu JC; Wang JJ; Li ZX
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(6):403-6. PubMed ID: 20367940
[TBL] [Abstract][Full Text] [Related]
55. Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.
Huang K; Sun B; Luo N; Guo H; Hu J; Peng J
Med Sci Monit; 2018 Jul; 24():4573-4582. PubMed ID: 29967316
[TBL] [Abstract][Full Text] [Related]
56. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma.
Wang XP; Xu M; Gao HF; Zhao JF; Xu KC
World J Gastroenterol; 2013 May; 19(19):2956-62. PubMed ID: 23704829
[TBL] [Abstract][Full Text] [Related]
57. [Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial].
Zhao M; Wu PH; Zeng YX; Xia JC; Zhang FJ; Xian LJ; Zhang YP; Zhou K; Fan WJ; Zhang L; Gao F; Zhou QM
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1823-8. PubMed ID: 17054858
[TBL] [Abstract][Full Text] [Related]
58. Locoregional immunochemotherapy in hepatocellular carcinoma.
Kountouras J; Boura P; Kouklakis G
Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.
Slavin S; Ackerstein A; Or R; Shapira MY; Gesundheit B; Askenasy N; Morecki S
Cancer Immunol Immunother; 2010 Oct; 59(10):1511-9. PubMed ID: 20563804
[TBL] [Abstract][Full Text] [Related]
60. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
